What we heard last year:

Slide Nine. So how are we going to do all this? We are still a very small company. We’ve enlisted a very experienced group in Eversana. So on Slide Nine, you’ll see the details of this group. They work all of these areas. These are areas that we have basically little to no experience in. So trying to roll this out on our own would be a bit of a slow-down and a hell of a learning experience. So we chose a path that minimizes financial exposure. It keeps our revenue base, and it maintains full ownership of the program going forward. So Eversana is an advanced company. They are purposely built to overcome external pressures and act as our commercializing engine. That’s their business model. They excel at key needs like patient services, channel, field solutions, plus they bolster that with other critical solutions to complete what we need to fully commercialize our product. But it’s not just their infrastructure. It’s the fact that they contractually commit to bold guarantees - guarantees that frankly, others cannot make. They cover up to 50% of the costs and the risks, paid back only out of future sales and not paid back if sales don’t exist. 3.5% royalty is an up-side for them on their side on North American sales. That’s a deal I would do any day of the week. I think this is an incredibly positive business model for a Phase III company like ours. The structure is also designed such that it has no encumbrance on future pharma deals. A low, reasonable buy-out has been set, so that if pharma wants to take over in the future, they can easily do it. So it is a marvelous system.

On Slide Ten, it shows that we’re just basically working with them and adding strength. They have 3,500 employees around the world, working in 25 locations. Working on over 150 brands right now, serving 80 countries. Our deal is for North America to start with, but this is an opening. We speak to them almost every day. They’re very excited. They view this as one of their top opportunities ever. And we happen to agree with them. It’s the dual mechanism that has them quite impressed. And remember these people are all from top 25 pharma companies and they know what they’re doing. So I think this was a brilliant move for the company to move forward and step in this way.

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/762730-reposting-with-link-included/messages/2320824#message